Extracellular proteolysis of apolipoprotein e (apoE) by secreted serine neuronal protease

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Tamboli, Irfan Y ^a   Heo, Dongeun ^a   Rebeck, G William ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E3; CHYMOTRYPSIN A; NEURITE PROMOTING FACTOR; NEUROSERPIN; SERINE PROTEINASE; ALPHA 1 ANTICHYMOTRYPSIN; APOLIPOPROTEIN E4; CHYMOTRYPSIN; CONDITIONED MEDIUM; NEUROPEPTIDE; SERINE PROTEINASE INHIBITOR;

ANIMAL CELL; ARTICLE; BRAIN CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; ENDOCYTOSIS; ENZYME ACTIVITY; EXTRACELLULAR SPACE; GLIAL CELL CULTURE; HIPPOCAMPAL NEURONAL CULTURE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LYSOSOME; MASS SPECTROMETRY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PURIFICATION; PROTEIN SECRETION; RAT; ZYMOGRAPHY; AMINO ACID SEQUENCE; ANIMAL; BRAIN; CELL CULTURE; CHEMISTRY; CONDITIONED MEDIUM; DRUG EFFECTS; GLIA; METABOLISM; MOLECULAR GENETICS; NERVE CELL; PYRAMIDAL NERVE CELL;

ALPHA 1-ANTICHYMOTRYPSIN; AMINO ACID SEQUENCE; ANIMALS; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN; CELLS, CULTURED; CHYMOTRYPSIN; CULTURE MEDIA, CONDITIONED; EXTRACELLULAR SPACE; HUMANS; MOLECULAR SEQUENCE DATA; NEUROGLIA; NEURONS; NEUROPEPTIDES; PROTEOLYSIS; PYRAMIDAL CELLS; RATS; SERINE PROTEASES; SERPINS;

EID: 84899796613     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093120     Document Type: Article

References (77)

1. Selkoe DJ (2011) Alzheimer's disease. Cold Spring Harb Perspect Biol 3. doi:10.1101/cshperspect.a004457
2. Masters CL, Beyreuther K (1998) Alzheimer's disease. BMJ 316: 446-448.
3. Haass C, Kaether C, Thinakaran G, Sisodia S (2012) Trafficking and Proteolytic Processing of APP. Cold Spring Harb Perspect Med 2: a006270. doi:10.1101/cshperspect.a006270
4. De Strooper B, Vassar R, Golde T (2010) The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 6: 99-107. doi:10.1038/nrneurol.2009.218
5. Weisgraber KH, Mahley RW (1996) Human apolipoprotein E: the Alzheimer's disease connection. FASEB J 10: 1485-1494. (Pubitemid 26384445)
6. Strittmatter WJ, Roses AD (1996) Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci 19: 53-77. doi:10.1146/annurev.ne.19.030196.000413 (Pubitemid 26080822)
7. Verghese PB, Castellano JM, Holtzman DM (2011) Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 10: 241-252. doi:10.1016/S1474-4422(10)70325-2
8. Tanzi RE (2012) The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2. doi:10.1101/cshperspect.a006296
9. Rebeck GW, Reiter JS, Strickland DK, Hyman BT (1993) Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 11: 575-580. (Pubitemid 23321768)
10. Huang Y, Weisgraber KH, Mucke L, Mahley RW (2004) Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease. J Mol Neurosci 23: 189-204. doi:10.1385/JMN:23: 3:189 (Pubitemid 41389385)
11. Leduc V, Domenger D, De Beaumont L, Lalonde D, Bélanger-Jasmin S, et al. (2011) Function and comorbidities of apolipoprotein e in Alzheimer's disease. Int J Alzheimers Dis 2011: 974361. doi:10.4061/2011/974361
12. Tai LM, Youmans KL, Jungbauer L, Yu C, Ladu MJ (2011) Introducing Human APOE into Ab Transgenic Mouse Models. Int J Alzheimers Dis 2011: 810981. doi:10.4061/2011/810981
13. Irizarry MC, Cheung BS, Rebeck GW, Paul SM, Bales KR, et al. (2000) Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid beta-peptide deposition in homozygous APP(V717F) transgenic mice. Acta Neuropathol 100: 451-458.
14. Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, et al. (2012) Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J Neurosci 32: 15181-15192. doi:10.1523/JNEUROSCI.1542- 12.2012
15. Kim J, Basak JM, Holtzman DM (2009) The role of apolipoprotein E in Alzheimer's disease. Neuron 63: 287-303. doi:10.1016/j.neuron.2009.06.026
16. Zlokovic B V (2013) Cerebrovascular Effects of Apolipoprotein E: Implications for Alzheimer Disease. JAMA Neurol 70: 1-5. doi:10.1001/jamaneurol. 2013.2152
17. Jiang Q, Lee CYD, Mandrekar S, Wilkinson B, Cramer P, et al. (2008) ApoE promotes the proteolytic degradation of Abeta. Neuron 58: 681-693. doi:10.1016/j.neuron.2008.04.010 (Pubitemid 351778466)
18. Hyman BT, Strickland D, Rebeck GW (2000) Role of the low-density lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer disease. Arch Neurol 57: 646-650. (Pubitemid 30252798)
19. Utter S, Tamboli IY, Walter J, Upadhaya AR, Birkenmeier G, et al. (2008) Cerebral small vessel disease-induced apolipoprotein E leakage is associated with Alzheimer disease and the accumulation of amyloid beta-protein in perivascular astrocytes. J Neuropathol Exp Neurol 67: 842-856. doi:10.1097/NEN.0b013e3181836a71
20. Hawkes CA, Sullivan PM, Hands S, Weller RO, Nicoll JAR, et al. (2012) Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ε4 allele. PLoS One 7: e41636. doi:10.1371/journal.pone.0041636
21. Mahley RW, Huang Y (2012) Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron 76: 871-885. doi:10.1016/j.neuron.2012. 11.020
22. Vance JE, Hayashi H (2010) Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim Biophys Acta 1801: 806-818. doi:10.1016/j.bbalip.2010.02.007
23. Liu C-C, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9: 106-118. doi:10.1038/nrneurol.2012.263
24. Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, et al. (2008) Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci 28: 11445-11453. doi:10.1523/JNEUROSCI.1972-08.2008
25. Belinson H, Michaelson DM (2009) Pathological synergism between amyloid-beta and apolipoprotein E4-the most prevalent yet understudied genetic risk factor for Alzheimer's disease. J Alzheimers Dis 17: 469-481. doi:10.3233/JAD-2009-1065
26. Sullivan PM, Han B, Liu F, Mace BE, Ervin JF, et al. (2011) Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol Aging 32: 791-801. doi:10.1016/j.neurobiolaging.2009.05.011
27. Gregg RE, Zech LA, Schaefer EJ, Stark D, Wilson D, et al. (1986) Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest 78: 815-821. doi:10.1172/JCI112645 (Pubitemid 16024820)
28. Wildsmith KR, Basak JM, Patterson BW, Pyatkivskyy Y, Kim J, et al. (2012) In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. PLoS One 7: e38013. doi:10.1371/journal.pone.0038013
29. Elliott DA, Tsoi K, Holinkova S, Chan SL, Kim WS, et al. (2011) Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiol Aging 32: 257-271. doi:10.1016/j.neurobiolaging.2009.02.006
30. Marques MA, Owens PA, Crutcher KA (2004) Progress toward identification of protease activity involved in proteolysis of apolipoprotein e in human brain. J Mol Neurosci 24: 73-80. doi:10.1385/JMN:24:1:073 (Pubitemid 41359170)
31. Zhou W, Scott SA, Shelton SB, Crutcher KA (2006) Cathepsin D-mediated proteolysis of apolipoprotein E: possible role in Alzheimer's disease. Neuroscience 143: 689-701. doi:10.1016/j.neuroscience.2006.08.019 (Pubitemid 44751361)
32. Brecht WJ, Harris FM, Chang S, Tesseur I, Yu G-Q, et al. (2004) Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 24: 2527-2534. doi:10.1523/JNEUROSCI.4315-03.2004 (Pubitemid 38327965)
33. Cho HS, Hyman BT, Greenberg SM, Rebeck GW (2001) Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. J Neuropathol Exp Neurol 60: 342-349 (Pubitemid 32274049)
34. Aizawa Y, Fukatsu R, Takamaru Y, Tsuzuki K, Chiba H, et al. (1997) Amino-terminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer's disease-affected brains: a possible role for apolipoprotein E in Alzheimer's disease. Brain Res 768: 208-214 (Pubitemid 27433493)
35. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, et al. (2003) Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A 100: 10966-10971. doi:10.1073/pnas.1434398100 (Pubitemid 37140136)
36. Lee CJ, Ansell JE (2011) Direct thrombin inhibitors. Br J Clin Pharmacol 72: 581-592. doi:10.1111/j.1365-2125.2011.03916.x
37. Gorodkiewicz E, Regulska E, Wojtulewski K (2011) Development of an SPR imaging biosensor for determination of cathepsin G in saliva and white blood cells. Mikrochim Acta 173: 407-413. doi:10.1007/s00604-011-0569-4
38. Kanemaru K, Meckelein B, Marshall DC, Sipe JD, Abraham CR (1996.) Synthesis and secretion of active alpha 1-antichymotrypsin by murine primary astrocytes. Neurobiol Aging 17: 767-771. (Pubitemid 26348878)
39. Abraham CR (2001) Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease. Neurobiol Aging 22: 931-936.
40. Miranda E, Lomas DA (2006) Neuroserpin: a serpin to think about. Cell Mol Life Sci 63: 709-722. doi:10.1007/s00018-005-5077-4
41. Schuster MG, Enriquez PM, Curran P, Cooperman BS, Rubin H (1992) Regulation of neutrophil superoxide by antichymotrypsin-chymotrypsin complexes. J Biol Chem 267: 5056-5059.
42. Kilpatrick L, Johnson JL, Nickbarg EB, Wang ZM, Clifford TF, et al. (1991) Inhibition of human neutrophil superoxide generation by alpha 1-antichymotrypsin. J Immunol 146: 2388-2393.
43. Jones PB, Adams KW, Rozkalne A, Spires-Jones TL, Hshieh TT, et al. (2011) Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid-β in human Alzheimer brain. PLoS One 6: e14586. doi:10.1371/journal.pone.0014586
44. Tomomura A, Yamada H, Itagaki K, Fujimoto K, Katoh S (2002) Rat brain expresses serum calcium-decreasing factor (caldecrin). Neurosci Lett 317: 17-20. (Pubitemid 34066507)
45. Yoshida S, Shiosaka S (1999) Plasticity-related serine proteases in the brain (review). Int J Mol Med 3: 405-409.
46. Korkmaz B, Moreau T, Gauthier F (2008) Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions. Biochimie 90: 227-242. doi:10.1016/j.biochi.2007.10.009 (Pubitemid 351187763)
47. Bu G (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10: 333-344. doi:10.1038/nrn2620
48. Wernette-Hammond ME, Lauer SJ, Corsini A, Walker D, Taylor JM, et al. (1989) Glycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194. J Biol Chem 264: 9094-9101. (Pubitemid 19151641)
49. Lee Y, Kockx M, Raftery MJ, Jessup W, Griffith R, et al. (2010) Glycosylation and sialylation of macrophage-derived human apolipoprotein E analyzed by SDS-PAGE and mass spectrometry: evidence for a novel site of glycosylation on Ser290. Mol Cell Proteomics 9: 1968-1981. doi:10.1074/mcp. M900430-MCP200
50. Shuvaev V V., Fujii J, Kawasaki Y, Itoh H, Hamaoka R, et al. (1999) Glycation of apolipoprotein E impairs its binding to heparin: identification of the major glycation site. Biochim Biophys Acta - Mol Basis Dis 1454: 296-308. doi:10.1016/S0925-4439(99)00047-2
51. Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, et al. (2000) Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem J 348 Pt 2: 359-365. (Pubitemid 30345209)
52. Baker C, Belbin O, Kalsheker N, Morgan K (2007) SERPINA3 (aka alpha-1-antichymotrypsin). Front Biosci 12: 2821-2835.
53. Porcellini E, Davis EJ, Chiappelli M, Ianni E, Di Stefano G, et al. (2008) Elevated plasma levels of alpha-1-anti-chymotrypsin in age-related cognitive decline and Alzheimer's disease: a potential therapeutic target. Curr Pharm Des 14: 2659-2664.
54. Potter H, Wefes IM, Nilsson LN (2001) The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiol Aging 22: 923-930. (Pubitemid 34066560)
55. Licastro F, Campbell IL, Kincaid C, Veinbergs I, Van Uden E, et al. (1999) A role for apoE in regulating the levels of alpha-1-antichymotrypsin in the aging mouse brain and in Alzheimer's disease. Am J Pathol 155: 869-875. (Pubitemid 29426833)
56. Vitek MP, Brown CM, Colton CA (2009) APOE genotype-specific differences in the innate immune response. Neurobiol Aging 30: 1350-1360. doi:10.1016/j.neurobiolaging.2007.11.014
57. Pocivavsek A, Burns MP, Rebeck GW (2009) Low-density lipoprotein receptors regulate microglial inflammation through c-Jun N-terminal kinase. Glia 57: 444-453. doi:10.1002/glia.20772
58. Zhu Y, Nwabuisi-Heath E, Dumanis SB, Tai LM, Yu C, et al. (2012) APOE genotype alters glial activation and loss of synaptic markers in mice. Glia 60: 559-569. doi:10.1002/glia.22289
59. Aguzzi A, Barres BA, Bennett ML (2013) Microglia: scapegoat, saboteur, or something else? Science 339: 156-161. doi:10.1126/science.1227901
60. Mandrekar-Colucci S, Landreth GE (2010) Microglia and inflammation in Alzheimer's disease. CNS Neurol Disord Drug Targets 9: 156-167.
61. Czirr E, Wyss-Coray T (2012) The immunology of neurodegeneration. J Clin Invest 122: 1156-1163. doi:10.1172/JCI58656
62. Thal DR, Capetillo-Zarate E, Schultz C, Rüb U, Saido TC, et al. (2005) Apolipoprotein E co-localizes with newly formed amyloid beta-protein (Abeta) deposits lacking immunoreactivity against N-terminal epitopes of Abeta in a genotype-dependent manner. Acta Neuropathol 110: 459-471. doi:10.1007/s00401-005-1053-1 (Pubitemid 41672339)
63. Tamboli IY, Prager K, Thal DR, Thelen KM, Dewachter I, et al. (2008) Loss of gamma-secretase function impairs endocytosis of lipoprotein particles and membrane cholesterol homeostasis. J Neurosci 28: 12097-12106. doi:10.1523/JNEUROSCI.2635-08.2008
64. Wisniewski T, Lalowski M, Golabek A, Vogel T, Frangione B (1995) Is Alzheimer's disease an apolipoprotein E amyloidosis? Lancet 345: 956-958.
65. Morrow JA, Hatters DM, Lu B, Hochtl P, Oberg KA, et al. (2002) Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. J Biol Chem 277: 50380-50385. doi:10.1074/jbc.M204898200 (Pubitemid 36042188)
66. Cramer PE, Cirrito JR, Wesson DW, Lee CYD, Karlo JC, et al. (2012) ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335: 1503-1506. doi:10.1126/science.1217697
67. Kim J, Eltorai AEM, Jiang H, Liao F, Verghese PB, et al. (2012) Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Ab amyloidosis. J Exp Med 209: 2149-2156. doi:10.1084/jem.20121274
68. Terwel D, Steffensen KR, Verghese PB, Kummer MP, Gustafsson J-Å, et al. (2011) Critical role of astroglial apolipoprotein E and liver X receptor-a expression for microglial Aβ phagocytosis. J Neurosci 31: 7049-7059. doi:10.1523/JNEUROSCI.6546-10.2011
69. Kline A (2012) Apolipoprotein E, amyloid-β clearance and therapeutic opportunities in Alzheimer's disease. Alzheimers Res Ther 4: 32. doi:10.1186/alzrt135
70. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, et al. (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485: 512-516. doi:10.1038/nature11087
71. Nakamura T, Watanabe A, Fujino T, Hosono T, Michikawa M (2009) Apolipoprotein E4 (1-272) fragment is associated with mitochondrial proteins and affects mitochondrial function in neuronal cells. Mol Neurodegener 4: 35. doi:10.1186/1750-1326-4-35
72. Ghosal K, Stathopoulos A, Thomas D, Phenis D, Vitek MP, et al. (2012) The Apolipoprotein-E-Mimetic COG112 Protects Amyloid Precursor Protein Intracellular Domain-Overexpressing Animals from Alzheimer's Disease-Like Pathological Features. Neurodegener Dis. doi:10.1159/000341299
73. Vitek MP, Christensen DJ, Wilcock D, Davis J, Van Nostrand WE, et al. (2012) APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer's disease transgenics. Neurodegener Dis 10: 122-126. doi:10.1159/000334914
74. Minami SS, Cordova A, Cirrito JR, Tesoriero JA, Babus LW, et al. (2010) ApoE mimetic peptide decreases Abeta production in vitro and in vivo. Mol Neurodegener 5: 16. doi:10.1186/1750-1326-5-16
75. Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, et al. (2006) Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci U S A 103: 18787-18792. doi:10.1073/pnas.0604011103 (Pubitemid 44913488)
76. Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, et al. (2009) Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 64: 632-644. doi:10.1016/j.neuron.2009.11.013
77. Mahley RW, Huang Y (2012) Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology. J Med Chem 55: 8997-9008. doi:10.1021/jm3008618